1. Home
  2. LCTX vs AMWL Comparison

LCTX vs AMWL Comparison

Compare LCTX & AMWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lineage Cell Therapeutics Inc.

LCTX

Lineage Cell Therapeutics Inc.

HOLD

Current Price

$1.46

Market Cap

407.7M

Sector

Health Care

ML Signal

HOLD

Logo American Well Corporation

AMWL

American Well Corporation

HOLD

Current Price

$5.66

Market Cap

92.0M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
LCTX
AMWL
Founded
1990
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Retail: Computer Software & Peripheral Equipment
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
407.7M
92.0M
IPO Year
1996
2020

Fundamental Metrics

Financial Performance
Metric
LCTX
AMWL
Price
$1.46
$5.66
Analyst Decision
Strong Buy
Hold
Analyst Count
2
7
Target Price
$6.00
$7.42
AVG Volume (30 Days)
1.1M
65.1K
Earning Date
03-05-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
57.06
EPS
N/A
N/A
Revenue
$14,556,000.00
N/A
Revenue This Year
$55.75
N/A
Revenue Next Year
$2.96
$4.24
P/E Ratio
N/A
N/A
Revenue Growth
53.24
N/A
52 Week Low
$0.37
$3.71
52 Week High
$2.09
$9.15

Technical Indicators

Market Signals
Indicator
LCTX
AMWL
Relative Strength Index (RSI) 32.08 55.96
Support Level $0.94 $4.48
Resistance Level $1.84 $5.81
Average True Range (ATR) 0.11 0.35
MACD -0.04 -0.02
Stochastic Oscillator 1.85 59.09

Price Performance

Historical Comparison
LCTX
AMWL

About LCTX Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.

About AMWL American Well Corporation

American Well Corp is an enterprise platform and software company digitally enabling hybrid care by offering payers and health systems a technology-enabled care platform. The Amwell Platform, its cloud-based enablement platform, digitally enables a scalable healthcare experience across all care settings by enabling critical services like virtual primary care, urgent care, clinical partner programs, scheduling visits, etc. Additionally, the healthcare providers can use the platform to access familiar workflows for taking notes, prescribing, referencing clinical treatment guidelines, and other related activities. The firm also offers various paid services, including licensed clinical staffing, implementation support, workflow design, etc, to help clients execute their hybrid care strategies.

Share on Social Networks: